Table 3.

Haematological and biochemical changes observed in adjuvant arthritis studies

	Haematological changes
	Red lineage		White lineage		Biochemical changes
AIA	RBC/HTC	↓	Total leukocytes	↑↑↑	Glucose	↓↓	ALP	↔
	Hgb	↓	Neutrophils	↑↑↑↑	TG	↓↓↓	ALT	↓↓↓
	Reticulocytes	↑↑↑	Lymphocytes	↔	CHOL	↔	AST	↓
	Platelets	↑↑↑	Monocytes	↑↑↑
Teriflunomide	RBC/HTC	↔	Total leukocytes	↓↓	Glucose	↔	ALP	↓↓
	Hgb	↔	Neutrophils	↓↓↓	TG	↔	ALT	↔
	Reticulocytes	↓	Lymphocytes	↓↓	CHOL	↔	AST	↔
	Platelets	↔	Monocytes	↓↓
AL8697	RBC/HTC	↔	Total leukocytes	↑↑	Glucose	↑	ALP	↔
	Hgb	↔	Neutrophils	↑↑	TG	↔	ALT	↔
	Reticulocytes	↔	Lymphocytes	↔	CHOL	↑↑	AST	↔
	Platelets	↓↓	Monocytes	↑↑
Tofacitinib	RBC/HTC	↔	Total leukocytes	↓↓	Glucose	↔	ALP	↔
	Hgb	↔	Neutrophils	↓↓↓	TG	↔	ALT	↑↑↑
	Reticulocytes	↓↓	Lymphocytes	↓↓	CHOL	↑↑	AST	↔
	Platelets	↓↓	Monocytes	↔

Changes in AIA refer to the induced versus the un-induced control. Changes in treatment groups refer to each treatment group versus the induced control. Results are shown for teriflunomide (3 mg·kg⁻¹ qd), AL8697 (10 mg·kg⁻¹ qd) and tofacitinib (10 mg·kg⁻¹ bid); except for biochemical changes for teriflunomide at 10 mg·kg⁻¹. Only parameters with significant changes in any treatment group are shown. ↔: no change; ↓,↑: 5–20 % change; ↓↓,↑↑: 21–50% change; ↓↓↓,↑↑↑: 51–100% change; ↑↑↑↑: > 100%.

RBC, red blood cell count; HTC, hematocrit; Hgb, haemoglobin; TG, triglycerides; CHOL total cholesterol.